Search results
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 1 day agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Fact Check: Study does not say COVID vaccines may have fuelled excess deaths
Reuters· 2 days agoA newly released study does not say COVID-19 vaccines may have fuelled excess deaths across the...
US ran secret anti-vax campaign to undermine China’s COVID efforts: Report
Al Jazeera· 7 hours agoAt the height of the COVID-19 pandemic, the United States military launched a secret campaign to...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 5 hours agoShortly after, the FDA accepted the advisers' advice but said it would continue to monitor the...
Is It Too Late to Buy Novavax Stock?
Motley Fool via Yahoo Finance· 14 hours agoJust be aware that the bullishness only goes so far. The consensus analyst price target on the healthcare stock is $17.50, which is only about 9% higher...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 3 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
Texas House approves ban on COVID-19 vaccine mandates by private employers
KRGV Rio Grande Valley· 5 days agoSign up for The Brief, The Texas Tribune’s daily newsletter that keeps readers up to speed on the...
Moderna president: Company outlook 'stabilizing' thanks to new flu-COVID vaccine data
Yahoo Finance via AOL· 3 days agoModerna president Stephen Hoge knows investors are waiting to see the company grow in a big way and...
Aaron Rodgers’ descent into the right-wing fever swamps
Media Matters· 3 days agoWhat began publicly as a hesitancy to get vaccinated for COVID-19 appears to have devolved, with the...
3 Reasons to Buy Moderna Stock
Motley Fool via Yahoo Finance· 7 days agoAlthough Moderna (NASDAQ: MRNA) is now a somewhat famous biotech, it was a relatively unknown, clinical-stage company just five years ago. Its success in...
